Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors

Thomas Collot 1, 2, 3, 4 Jean-David Fumet 2, 1, 3, 4 Quentin Klopfenstein 1, 3, 4 Julie Vincent 2 Leila Bengrine 2 François Ghiringhelli 2, 3, 4, 1, *
* Auteur correspondant
3 Plateforme de transfert en biologie cancérologique [Dijon]
CEP - Centre d'épidémiologie des populations, CRLCC - CGFL - Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc
Abstract : AIM: To assess and report the efficacy of and tolerance to bevacizumab-based chemotherapy in treatment outcome of metastatic poorly differentiated neuroendocrine tumors. PATIENTS AND METHODS: From 2007 to 2018, 11 consecutive patients with metastatic poorly differentiated neuroendocrine treated in first- or second-line with bevacizumab-based chemotherapies were included in this monocentric retrospective cohort. Tumor response was evaluated by computed tomographic scans. RESULTS: Administered treatment included 5-fluorouracil and irinotecan (FOLFIRI) bevacizumab, 5-fluorouracil and oxaliplatin (FOLFOX) bevacizumab and 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRINOX) bevacizumab for four, two and five patients, respectively. Three were treated in first-line and eight in second-line after cisplatin-etoposide regimen. Using Response Evaluation Criteria in Solid Tumors, partial response was observed for seven patients, and stable disease for one patient, giving a response rate of 63.6% (95% confidence interval=35.2-92.1%) and disease control rate of 72.7% (95% confidence interval=46.6-99.0%). All patients had died by the time of analysis, median progression-free survival was 14 months, and median overall survival was 15.3 months. Observed toxicity with such protocols was classical with 10 grade 3-4 toxic events, including three of hematological toxicity, three of infection, and three of digestive toxicity. CONCLUSION: Bevacizumab-based chemotherapy gave surprising efficacy and safety in first-or second-line treatment for metastatic poorly differentiated neuroendocrine tumor in this retrospective cohort. Prospective randomized trials of such therapy are warranted. Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01925108
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : vendredi 16 novembre 2018 - 14:44:40
Dernière modification le : lundi 13 mai 2019 - 14:47:15

Identifiants

Citation

Thomas Collot, Jean-David Fumet, Quentin Klopfenstein, Julie Vincent, Leila Bengrine, et al.. Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors. Anticancer Research, International Institute of Anticancer Research, 2018, 38 (10), pp.5963 - 5968. ⟨http://ar.iiarjournals.org/content/38/10/5963.long⟩. ⟨10.21873/anticanres.12943⟩. ⟨hal-01925108⟩

Partager

Métriques

Consultations de la notice

25